ImmunoCellular Therapeutics, Ltd. (IMUC.OB) Picks Averion to Conduct Phase II Study for Leading Glioblastoma Candidate
ImmunoCellular, www.imuc.com – the clinical-stage biotech firm developing therapies for brain and other cancers which focus on utilizing the body’s own immunological system, reported contracting with clinical research organization Averion International Corp. today for the purposes of conducting a planned Phase II study of the Company’s leading cancer-vaccine candidate ICT-107 for GBM (glioblastoma multiforme). President and CEO of IMUC, Manish Singh, Ph.D., highlighted Averion’s globally recognized reputation as a leader with vast experience in brain cancer, and characterized the selection as ideal for taking ICT-107, the dendritic cell-based vaccine which targets multiple tumor-associated antigens for GBM (and which recently completed…